MIRA Pharmaceuticals, Inc. (MIRA)

USD 1.05

(-1.87%)

EBITDA Summary of MIRA Pharmaceuticals, Inc.

MIRA Pharmaceuticals, Inc.'s latest annual EBITDA in 2023 was - USD , up 50.96% from previous year.
MIRA Pharmaceuticals, Inc.'s latest quarterly EBITDA in 2024 Q2 was -1.73 Million USD , down 0.0% from previous quarter.
MIRA Pharmaceuticals, Inc. reported an annual EBITDA of -7.04 Million USD in 2022, down -227.48% from previous year.
MIRA Pharmaceuticals, Inc. reported an annual EBITDA of -2.15 Million USD in 2021, down -3082.26% from previous year.
MIRA Pharmaceuticals, Inc. reported a quarterly EBITDA of -1.73 Million USD for 2024 Q2, down 0.0% from previous quarter.
MIRA Pharmaceuticals, Inc. reported a quarterly EBITDA of -1.33 Million USD for 2023 Q1, up 0.62% from previous quarter.

Annual EBITDA Chart of MIRA Pharmaceuticals, Inc. (2023 - 2020)

Historical Annual EBITDA of MIRA Pharmaceuticals, Inc. (2023 - 2020)

Year	EBITDA	EBITDA Growth
2023	- USD	50.96%
2022	-7.04 Million USD	-227.48%
2021	-2.15 Million USD	-3082.26%
2020	- USD	0.0%

Year	EBITDA	EBITDA Growth
2024 Q1	-1.76 Million USD	0.0%
2024 Q2	-1.73 Million USD	0.0%
2023 Q1	-1.33 Million USD	0.62%
2023 Q3	-3.16 Million USD	-225.71%
2023 FY	- USD	-20.97%
2023 Q4	-3.05 Million USD	3.28%
2023 Q2	-970.22 Thousand USD	27.56%
2022 Q3	-1.8 Million USD	25.29%
2022 FY	- USD	-227.48%
2022 Q1	-1.47 Million USD	0.0%
2022 Q4	-1.34 Million USD	25.47%
2022 Q2	-2.42 Million USD	-64.54%
2021 Q1	-52.05 Thousand USD	0.0%
2021 FY	- USD	-3082.26%
2020 FY	- USD	0.0%

Peer EBITDA Comparison of MIRA Pharmaceuticals, Inc.

Name	EBITDA	EBITDA Difference
Amgen Inc.	12.23 Billion USD	100.0%
AstraZeneca PLC	12.97 Billion USD	100.0%
Biogen Inc.	2.37 Billion USD	100.0%
Gilead Sciences, Inc.	10.49 Billion USD	100.0%
Scilex Holding Company	-109.1 Million USD	100.0%
Scilex Holding Company	-109.1 Million USD	100.0%